Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lorcaserin

- PMLiVE

Early 2013 sees drug filings, launches and approvals in Japan

Includes medicines from Bayer, Takeda, Astellas and Eisai

EISAI

Eisai’s farletuzumab fails ovarian cancer trial

Unable to improve progression-free survival

Novartis building

Novartis parts with Eisai to go it alone with COPD drugs

Ends co-promotion agreement for Onbrez, Seebri and QVA149

- PMLiVE

Takeda ends obesity alliance with Amylin

Comes more than a year after development of lead product was pulled

EISAI

Eisai forms neurology partnership with UCL

Unique ‘therapeutic innovation group’ will research Alzheimer's, Parkinson's and other brain conditions

Eisai: Bucking the trend with R&D growth

PME’s emerging companies series continues with a firm that’s committed to research as it expands its commercial position

US HHS secretary Sebelius subpoenaed over health reform promotion

House Republicans demand investigation into Affordable Care Act PR

- PMLiVE

Obama victory ensures US healthcare reforms will continue

Republican hopeful Mitt Romney unable to act on plan to repeal Affordable Care Act

Eisai’s epilepsy drug Fycompa gets green light in US

Japanese firm predicts global sales of more than $1bn at peak

- PMLiVE

Vivus fails to get European backing for obesity treatment Qsiva

EMA raises concerns about drug’s cardiovascular safety

- PMLiVE

VIDEO: Eisai manufacturing plans shows UK is recovering from ‘shock’ of Pfizer/AZ cutbacks

David Willetts says life sciences industry has future in UK at opening of Fycompa manufacturing site

- PMLiVE

Vivus expects knockback from EMA for obesity drug

Setback comes despite US approval for Qsiva/Qsymia

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links